Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

119.63 +0.70 (+0.59%)

Official Closing Price Updated: 7:00 PM EDT, Mar 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

99 100 Next >

Merck Makes Big Bet On Flu Protection With Cidara Buyout ↗

November 14, 2025

Merck (NYSE: MRK) to acquire Cidara (NASDAQ: CDTX) for $9.2 billion, diversifying its portfolio with CD388.

Via Benzinga

Merck To Buy Cidara In $9.2B Deal To Strengthen Antiviral Portfolio ↗

November 14, 2025

With the new deal, Merck would gain access to CD388, currently in late-stage development, and designed to prevent influenza infection in individuals at higher risk of influenza complications.

Via Stocktwits

Topics Intellectual Property

Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

November 14, 2025

From Merck & Co., Inc.

Via Business Wire

Cidara Therapeutics Stock Soars 42% After-Hours On Merck Buyout Buzz — Retail Traders Eye A Potential Blowout Premium ↗

November 13, 2025

Via Stocktwits

Tech Sector Tremors: Is the AI Bubble Deflating, and What's Next for the Market?

November 13, 2025

As of mid-November 2025, a palpable unease has settled over the technology sector, long the darling of investors and the primary engine of market growth. After a period of unprecedented outperformance,...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Merck to Participate in the Jefferies Global Healthcare Conference in London

November 13, 2025

From Merck & Co., Inc.

Via Business Wire

Should You Forget Pfizer and Buy This Magnificent Drug Stock Instead? ↗

November 13, 2025

Pfizer has a huge dividend yield and a high payout ratio compared to Merck, which could make Merck the more attractive dividend stock.

Via The Motley Fool

Topics Intellectual Property

Is the Schwab U.S. Dividend Equity ETF the "Ultimate Retirement Fund" for Investors? ↗

November 13, 2025

A $10,000 investment in this diversified fund at its 2011 inception would be worth $51,000 today.

Via The Motley Fool

Topics ETFs Economy Retirement

The Data Drought of 2024: Recalling the Urgent Call for November Jobs and CPI Figures Post-Shutdown

November 12, 2025

Washington D.C. – November 12, 2025 – Looking back from today, the critical period following a hypothetical, yet highly plausible, U.S. government shutdown in late 2024 served as a stark reminder of...

Via MarketMinute

Topics Economy

Nasdaq Stumbles: Tech Sector Faces Reality Check Amid Valuation Concerns and Sector Rotation

November 12, 2025

The Nasdaq Composite (NASDAQ: IXIC) experienced back-to-back losses on November 11 and 12, 2025, signaling a significant recalibration in the financial markets. This downturn, primarily driven by...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Dow Jones Soars to Unprecedented Heights as Market Cheers Government Shutdown Resolution

November 12, 2025

New York, NY – November 12, 2025 – The Dow Jones Industrial Average (DJIA) has shattered previous records, closing at an all-time high of 48,254.82 today, marking a significant milestone for the...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Unprecedented Market Anomaly: Gold and Silver Soar as Dow Breaches 48,000 Amidst Inflationary Fears and Geopolitical Tensions

November 12, 2025

The financial markets are currently exhibiting an extraordinary and complex phenomenon: both traditional safe-haven assets, gold and silver, are experiencing robust rallies, while the Dow Jones...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Dow Soars Past 48,000 as Gold and Silver Shine in a Market of Paradox

November 12, 2025

New York, NY – November 12, 2025 – In a remarkable display of market resilience and underlying tension, the Dow Jones Industrial Average (DJIA) has surged past the 48,000-point threshold, closing at an...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Dow Breaches 48,000 Milestone Amidst Government Shutdown Resolution Hopes, S&P 500 and Nasdaq Lag

November 12, 2025

The Dow Jones Industrial Average (DJIA) made history on Wednesday, November 12, 2025, surging past the 48,000-point mark for the first time ever, gaining nearly 380 points. This significant rally was...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

2 Strong Healthcare Stock Picks for Value Investors ↗

November 12, 2025

Value-driven plays abound in the top healthcare stocks.

Via The Motley Fool

Topics Intellectual Property

2 Stocks Down 13% and 34% to Buy Right Now ↗

November 12, 2025

It's been a year to forget for these two companies, but brighter days are ahead.

Via The Motley Fool

Topics Intellectual Property World Trade

Google To Run Ohio Data Centers On Solar Power From TotalEnergies ↗

November 12, 2025

TotalEnergies and Google have signed a 15-year PPA for renewable electricity. The deal aligns with both companies' goals.

Via Benzinga

Dow Jones Industrial Average Soars to Record High: A Nuanced Signal for the Economy

November 11, 2025

NEW YORK, NY – November 11, 2025 – The Dow Jones Industrial Average (DJIA) has reached an unprecedented milestone today, soaring to a new all-time high of 47,927.96, a robust gain of 559.33 points...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Dow Jones Industrial Average Soars to New All-Time High Amidst Shifting Market Dynamics

November 11, 2025

New York, NY – November 11, 2025 – The Dow Jones Industrial Average (DJIA) has today surged to an unprecedented all-time high, pushing past significant milestones and reinforcing a complex, yet largely...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Merck, Elanco, Myriad Genetics, Neogen, and Cigna Shares Are Soaring, What You Need To Know

November 11, 2025

A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid...

Via StockStory

Topics Artificial Intelligence Stocks

Exploring the top movers within the S&P500 index during today's session. ↗

November 11, 2025

Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.

Via Chartmill

What's going on in today's session: S&P500 movers ↗

November 11, 2025

Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.

Via Chartmill

Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market? ↗

November 11, 2025

Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs.

Via The Motley Fool

Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds

November 10, 2025

New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Cliff Asness: The Stock Market is Expensive, Not a Bubble – A Call for Rationality in a Less Efficient Market

November 10, 2025

New York, NY – November 10, 2025 – In a financial landscape often characterized by extremes, Cliff Asness, the influential co-founder of AQR Capital Management, offers a nuanced yet stark assessment of...

Via MarketMinute

Topics Economy

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial

November 09, 2025

From Merck & Co., Inc.

Via Business Wire

Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60% ↗

November 08, 2025

Merck said Saturday its new pill — a possible rival to Regeneron and Amgen — lowered high cholesterol by almost 60%.

Via Investor's Business Daily

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial

November 08, 2025

From Merck & Co., Inc.

Via Business Wire

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Herkimer College Pioneers New AI-Business Degree to Forge Future-Ready Workforce

November 07, 2025

Herkimer, NY – November 7, 2025 – In a significant move signaling a proactive response to the escalating demand for artificial intelligence (AI) expertise in the business world, Herkimer County...

Via TokenRing AI

Topics Artificial Intelligence Economy Fraud

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.